VIP nasal spray claims: what the science actually supports

What's this video probably claiming?

Based on the caption and hashtag context, this video is almost certainly positioning VIP (Vasoactive Intestinal Peptide) nasal spray as a wellness tool with broad systemic benefits, including respiratory support, improved circulation, and neurological function. The creator appears to frame the nasal route as a targeted delivery mechanism that bypasses typical barriers and gets VIP into both central and systemic circulation quickly. Given that Wells Pharmacy Network is a compounding pharmacy, the implicit pitch is likely that their compounded VIP spray is a legitimate, accessible option for people dealing with respiratory or autonomic symptoms. The hashtag "respiratorysupport" alongside "peptidetherapy" strongly suggests the video is aimed at people recovering from post-viral illness or mold-related illness (CIRS), two communities where VIP has become a buzzword. Whether the video acknowledges the regulatory status of compounded VIP is the question that matters most here.

What does the science actually show?

VIP is a real neuropeptide with legitimate pharmacology. It binds VPAC1 and VPAC2 receptors and does produce smooth muscle relaxation, bronchodilation, and vasodilation in controlled settings. Yadav et al. (2008, Annals of the New York Academy of Sciences) documented VIP's anti-inflammatory and immunomodulatory properties in animal models. The problem is that virtually all strong mechanistic research on VIP is preclinical. Human trials are sparse and narrow in scope. Shoemaker and House (2006, Neurotoxicology and Teratology) published a small pilot study suggesting intranasal VIP improved pulmonary arterial pressure and inflammatory markers in CIRS patients, but the sample size was under 20 and the study lacked a placebo arm. That pilot has since become the primary citation behind an enormous commercial ecosystem. One underpowered, uncontrolled pilot from 2006 is not a clinical evidence base. It is a hypothesis generator.

Where does the social media noise diverge from clinical reality?

The divergence is significant. Social media creators in the peptide space routinely present VIP nasal spray as an established therapy for post-COVID symptoms, mold illness, and autonomic dysfunction. The implication is that nasal delivery reliably gets VIP across the blood-brain barrier and into systemic circulation at therapeutically meaningful concentrations. That claim is not well established. VIP is a 28-amino acid peptide with a short plasma half-life estimated at under two minutes in circulation (Domschke et al., 1978, Gastroenterology). Nasal bioavailability for peptides of this molecular weight is typically poor without penetration enhancers, and formulation details from compounders are rarely disclosed publicly. The framing of "targeted delivery into the central and systemic circulation" in the caption reads as clinical precision. It is not supported by peer-reviewed pharmacokinetic data on intranasal VIP in humans.

What should you actually know?

Compounded VIP nasal spray is not FDA-approved. It is not equivalent to any approved drug product. The FDA has not evaluated compounded VIP for safety, efficacy, or consistent potency. That does not mean it is useless, but it does mean the burden of proof sits with the people selling it, not the people questioning it. If you are considering VIP therapy, specifically for CIRS or post-viral recovery, the conversation should happen with a physician who can review your inflammatory markers, your HERTSMI-2 or ERMI results if mold is suspected, and your full clinical picture. VIP should never be the first intervention. The Shoemaker Protocol, controversial as it is, at least frames VIP as a late-stage treatment after environmental remediation. Social media has stripped that context entirely and turned a niche compounded peptide into a general wellness product. That reframing is where the real risk lives.